Teva   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Petah Tiqva Israel (1901)

Organization Overview

First Clinical Trial
1991
NCT01400217
First Marketed Drug
1951
dyphylline (neothylline)
First NDA Approval
1951
dyphylline (neothylline)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. | Claudio Brandi, MD | Gamida Cell -Teva Joint Venture Ltd. | GATE PHARMS | GENERICS | IVAX SUB TEVA PHARMS | Merckle GmbH, Teva Ratiopharm | Santiago Bertone, MD | TEVA | TEVA BRANDED PHARM | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Branded Pharmaceutical Products, R&D Inc. | Teva Branded Pharmaceuticals Products R&D, Inc. | Teva Canada | Teva GBP | Teva GCO | Teva Global Respiratory Research | Teva GTC | Teva Nederland BV | Teva Neuroscience Canada | Teva Neuroscience, Inc. | TEVA PARENTERAL | TEVA PHARM | Teva Pharma | Teva Pharmaceutical Industries | Teva Pharmaceutical Industries, Ltd. | Teva Pharmaceuticals Development, Inc. | Teva Pharmaceuticals Europe | Teva Pharmaceuticals Industries LTD | Teva Pharmaceuticals USA | TEVA Pharmachemie | Teva Pharma GmbH | TEVA PHARMS | TEVA PHARMS INTL | TEVA PHARMS USA | TEVA PHARMS USA INC | TEVA RESPIRATORY LLC | Teva Respiratory R&D | Teva (v1) | Teva (v2) | TEVA WOMENS | Teva Women's Health | Teva Women's Health Research | US GENERICS, STERILES | WATSON LABS TEVA